⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
businesswire.com
INCY
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
businesswire.com
INCY
MIRM
インサイトのピボタルfrontMIND試験、タファシタマブ（Monjuvi®/Minjuvi®）併用療法で無増悪生存期間を有意に延長、未治療の高リスクDLBCL患者の病勢進行または死亡リスクを25%低減
businesswire.com
INCY
Die zulassungsrelevante frontMIND-Studie von Incyte zeigte, dass die Kombination mit Tafasitamab (Monjuvi®/Minjuvi®) das progressionsfreie Überleben signifikant verlängerte und das Risiko eines Krankheitsfortschritts oder des Todes bei Patienten...
businesswire.com
INCY
L’essai pivot frontMIND d’Incyte a montré que l’association à base de tafasitamab (Monjuvi®/Minjuvi®) prolongeait significativement la survie sans progression, réduisant de 25 % le risque de progression de la maladie ou de décès chez les patients...
businesswire.com
INCY
Resumen: El ensayo fundamental frontMIND de Incyte demostró que la combinación con tafasitamab (Monjuvi®/Minjuvi®) prolongó significativamente la supervivencia libre de progresión, lo que reduce en un 25 % el riesgo de progresión de la enfermedad o muerte...
businesswire.com
INCY
Riassunto: frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia...
businesswire.com
INCY
Samenvatting: Cruciale frontMIND-studie van Incyte heeft aangetoond dat de combinatie van tafasitamab (Monjuvi®/Minjuvi®) de progressievrije overleving significant verlengde en het risico op ziekteprogressie of overlijden met 25% verlaagde bij patiënten met...
businesswire.com
INCY
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ®/Minjuvi ®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
businesswire.com
INCY
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN